CompletedPhase 4

Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients

Pakistan82 participantsStarted 2023-04-01

Plain-language summary

Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema

Who can participate

Age range32 Years – 78 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with center involving diabetic macular edema on optical coherence tomography Exclusion Criteria: * Raised intraocular pressure * History of glaucoma * Corneal opacity * Vitreous hemorrhage * Proliferative diabetic retinopathy * Anti-VEGF injections in last 3 months * History of pan-retinal photocoagulation * Contraindications for anti-VEGF

What they're measuring

Central macular thickness

Timeframe: 3 months

Visual Acuity

Timeframe: 3 months

Trial details

NCT IDNCT06882551

SponsorKhyber Teaching Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-11-30

View on ClinicalTrials.gov More Diabetic Macular Edema (DME) trials